Please login to the form below

Not currently logged in

Bionor names executive management team additions

Three new starters including chief operating officer and interim CFO

edit-Sren-KellerHIV and deadly virus firm Bionor Pharma has revealed a number of new additions to its executive management team.

Søren Keller has been named as chief operating officer and interim chief financial officer. He has extensive experience as head of operation in public and private research intensive organisations and most recently served as director and general counsel to the management at Zealand Pharma.

Barbara A. Ruskin joins as general counsel and chief patient officer, effective from April 1. Ruskin has advised clients in the biotech and pharma industries for over 20 years and has a expertise in worldwide patient portfolio management, litigation strategies and corporate transactions.

Kamilla Rolsted also joins on April 1 as chief strategy and business officer. Rolstead has over 15 years of experience and has held numerous scientific and managerial positions, including director at Zealand Pharma where she headed strategy and planning.

David Solomon, president and CEO, commented: “I am delighted that Barbara Ruskin, Kamilla Rolsted and Søren Keller have joined Bionor. Together, they bring a wealth of experience to advance therapeutic vaccines for Bionor, and specifically will add operational strength to get our HIV functional cure approach advanced to patients and the markets.”

31st March 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Our higher purpose is to deliver better communication to increase and speed up the ability of patients to access better...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...